Bupivacaine extended release - Sonoran Biosciences
Alternative Names: SBG-004Latest Information Update: 11 Feb 2025
At a glance
- Originator Sonoran Biosciences
- Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Postoperative pain
Most Recent Events
- 11 Feb 2025 pharmacodynamics data from a preclinical study in Postoperative pain released by Sonoran Biosciences
- 02 Jan 2025 Sonoran Biosciences receives phase II SBIR grant from the National Institute of General Medical Sciences of the National Institutes of Health for Bupivacaine extended release formulation development in Postoperative pain
- 02 Jan 2025 Preclinical trials in Postoperative pain in USA (SC) prior to January 2025